What Пролатан Treats: Main Uses and Benefits

Пролатан (Latanoprost) is a recognized therapeutic agent in eye health, generally applied for the long-term management of diseases characterized by abnormally high pressure inside the eye. Its purpose is primarily focused on supporting the preservation of the visual field and reducing the risk of sight loss.

---

Sustained Reduction of Elevated Eye Pressure

This domain addresses the core problem of pathologically elevated intraocular pressure (IOP), which is often a silent risk factor. The medication is commonly used in conditions like Primary Open-Angle Glaucoma, Ocular Hypertension, and certain cases of Pediatric Glaucoma to provide a significant and sustained therapeutic reduction in this pressure. The key patient benefit is supporting long-term ocular stability to help ease the overall symptom load related to elevated pressure.

Protection and Prophylactic Use

This therapeutic area is relevant for easing the long-term impact of the condition. It is applied as a prophylactic agent in asymptomatic scenarios like Ocular Hypertension. It is relevant for managing the risk associated with developing irreversible optic nerve damage and subsequent visual field deterioration. This approach is important when supportive symptom management is appropriate for managing the heightened physiological stress linked to the condition.

---

Quick Fact: Relief for Pathologically Elevated IOP

The medication is commonly used in contexts involving chronic management of eye pressure and is considered relevant when supportive symptom management is appropriate for chronic conditions like glaucoma. It assists with maintaining functional stability and provides supportive relief when symptoms interfere with routine activities related to maintaining eye health.

Regulatory References

1. Official NIH/NLM Prescribing Information for Latanoprost

Eligibility Profile: Who Can and Cannot Use Пролатан

The eligibility for Пролатан (Latanoprost) is strictly defined by regulatory documents, focusing on patient status and pre-existing conditions.

Populations with Established Use

Пролатан is formally approved for use in adults and the elderly, and is generally considered eligible for use in certain pediatric patients.

Absolute Contraindications

Use is contraindicated and must be avoided in populations exhibiting:

• Known hypersensitivity to latanoprost or any excipients.
• Active herpes simplex keratitis or active intraocular inflammation (e.g., iritis or uveitis).

Restricted and Not Recommended Use

The medicine is not recommended for use in pregnant women or breast-feeding women as per regulatory guidance. Specific caution is required for patients with a history of herpetic keratitis, previous intraocular inflammation, or specific lens conditions like being aphakic or having a torn posterior lens capsule.

Age and Data Limitations

Safety and efficacy data are very limited for infants under one year of age. Use is not established for pre-term infants or in patients with certain conditions, including angle-closure or neovascular glaucoma.

Interactions with other medicines and products

This section details the officially documented drug-drug and product-drug interaction profile for Пролатан (Latanoprost) based strictly on governmental regulatory prescribing information.

Documented Pharmacodynamic and Procedural Interactions

The primary restrictions for Пролатан relate to co-administration with other ophthalmic drugs and members of its own pharmacological class.

Interaction Type	Interacting Substance/Class	Regulatory Restriction
Pharmacodynamic	Two or more Prostaglandin Analogs (e.g., Bimatoprost, Travoprost)	Co-administration is not recommended due to reports of paradoxical increases in Intraocular Pressure (IOP) or a reduction in the desired IOP-lowering effect.
Timing/Procedural	Other Topical Ophthalmic Medications	Must be administered at least five (5) minutes apart.

Timing Separation Requirement

Regulatory documents mandate an administration interval of at least five minutes when Пролатан is used concurrently with any other topical eye drops. This requirement is in place to prevent potential physical precipitation (which is observed in vitro with Thimerosal-containing products) and to ensure proper absorption and delivery of each medication.

Metabolic and Non-Drug Interactions

Official prescribing information does not list any specific interactions involving cytochrome P450 enzymes or drug transporters that significantly alter Пролатан's systemic exposure. Furthermore, no formal interactions have been established or documented in regulatory labeling regarding concomitant use with food, alcohol, herbal products, or supplements.

Specific Activation of Ocular Prostanoid Receptors

Пролатан's action is defined by a highly specific, localized pharmacodynamic sequence that directly targets the ocular fluid dynamics system. The drug's active form acts as an agonist at the FP receptor, a specific G protein-coupled receptor within the eye's ciliary body. This receptor activation initiates the primary molecular cascade and is a functional component in modulating local tissue responses through prostanoid signaling.

Modulation of Tissue Permeability and Fluid Outflow

Agonism of the FP receptor triggers an increase in Matrix Metalloproteinases (MMPs), which are enzymes that remodel the Extracellular Matrix (ECM). This enzymatic action alters the structural integrity within the tissues, particularly in the uveoscleral outflow pathway. This change in the mechanical properties of the tissue results in the enlargement of fluid channels and facilitates the flow of aqueous humor through the unconventional pathway, producing a measurable adjustment in fluid dynamics.

Official Administration Guidelines for Пролатан (Latanoprost)

These instructions define the proper use of the medicine, based on established administration protocols.

Instruction Category	Official Rule
Route of Administration	Topical ophthalmic (eye drops only).
Standard Dosing	One single drop in the affected eye(s).
Frequency	Once daily.
Timing	Recommended to be administered in the evening for optimal effect.
Maximum Dose	The dosage should not exceed once daily; more frequent administration may reduce the therapeutic effect.
Age-Group Rules	The standard once-daily dose is used for adults, including the elderly, and may be applied to children and adolescents.
Missed Dose	If a dose is missed, treatment should continue with the next scheduled dose as normal. Do not take a double dose to compensate.

Administration Procedure and Constraints

The correct application technique is essential for effective use. Patients are instructed to prevent the tip of the container from touching the eye, eyelid, or any other surface to avoid contamination.

Key constraints defined in clinical guidelines include:

• Contact Lenses: Soft contact lenses must be removed before instilling the drops and may be reinserted 15 minutes after administration.
• Multiple Eye Drops: If using other topical ophthalmic drugs, they should be administered at least five (5) minutes apart from Пролатан.
• Aseptic Technique: Following application, patients should gently close the eye and apply pressure to the inner corner of the eye near the nose (punctal occlusion) for one minute to minimize systemic absorption.

Following these mandatory procedural and scheduling requirements is necessary to align with the medicine's approved use protocol.

Research evidence / Overview of studies for Пролатан

Evidence for use in Primary Open-Angle Glaucoma and Ocular Hypertension

The foundation of the research for Пролатан involves numerous studies that research examined how Intraocular Pressure (IOP) evolved in two related conditions: Primary Open-Angle Glaucoma (POAG) and Ocular Hypertension (OHT). Research explored outcomes related to physiological strain or stress inside the eye. The evidence contributing to understanding symptom patterns generally comes from large-scale randomized controlled trials (RCTs).

Primary Open-Angle Glaucoma (POAG)

Research examined the use of Пролатан in adult and older adult populations with POAG. In these trials, researchers monitored the change in mean diurnal IOP and also explored functional measures like the time until visual field deterioration was observed in the populations. Findings describe patterns observed where subjects receiving the substance data show patterns related to the measurement of IOP changes compared to measurements taken at the study start. Furthermore, research describes patterns where a longer time before visual field deterioration was associated with the substance in some trials.

Ocular Hypertension (OHT)

The research explored the use of Пролатан in subjects with Ocular Hypertension, where IOP is elevated but nerve damage may not be apparent. The studies were often short-to-intermediate in duration and primarily monitored the percentage of IOP change from baseline. Studies report how IOP evolved in the observed populations, consistently indicating that the substance was associated with recorded changes in eye pressure measurements in the studied OHT populations. Long-term effects are not fully established regarding definitive evidence for preventing progression to glaucoma.

Long-Term Follow-up and Durability of Study Endpoints

This section contributes to the broader evidence landscape by synthesizing information from extended clinical trials and observational follow-up reports (typically 1–2 years in duration) that studies monitored outcomes related to maintaining pressure levels and assessing long-term changes to the visual field. Long-term effects are not fully established regarding functional outcomes for periods extending beyond two years; the available data relies heavily on observational settings, rather than formal controlled interventional trials.

Key Studies & References

1. Latanoprost systemic exposure in pediatric and adult patients with glaucoma: a phase 1, open-label study.

Common questions about Пролатан (FAQ)

Q: What are the known long-term effects of using Пролатан for several years?

Regulatory documents state that pigmentation changes to the iris are patterns that may increase over time with continued use and are officially noted as likely permanent even after treatment stops. However, changes to the eyelashes (like increased length or thickness) and darkening of the eyelid skin have been reported to be reversible in some patients once the medicine is discontinued. The full long-term effects of increased pigmentation beyond five years are not fully established in available study data.

---

Q: Do the common side effects of Пролатан usually go away over time?

The change in the color of the iris (the colored part of the eye) caused by Пролатан is considered likely permanent and may not go away even if you stop using the medicine. Other changes, such as increased eyelash growth and the darkening of the eyelid skin, have been reported to be reversible in some patients after they discontinue treatment.

---

Q: How quickly does Пролатан start to reduce eye pressure after the first use?

Official pharmacological data indicates that the medicine begins to lower the pressure inside the eye (intraocular pressure) approximately 3 to 4 hours after the first drop is administered.

---

Q: What is the expected time frame to notice the full effect of Пролатан?

Studies and official information indicate that the maximum pressure-lowering effect of the medication is generally reached after 8 to 12 hours following administration.

---

Q: What is the general guidance on continuing to use Пролатан even if symptoms feel controlled?

The medicine is formally indicated for the long-term management of chronic conditions such as glaucoma and ocular hypertension, and its purpose is defined as helping to sustain pressure levels over time.

---

Q: Does Пролатан interact negatively with alcohol consumption?

Official regulatory prescribing information does not list any formal interactions between Пролатан and alcohol consumption.

---

Q: Are there specific medical conditions, besides glaucoma, that would prevent someone from using Пролатан?

Yes, regulatory documents list specific conditions that contraindicate its use. This includes having a known hypersensitivity to the drug's components or having active intraocular inflammation, such as iritis or uveitis.

---

Q: Is Пролатан used only for glaucoma, or for other conditions as well?

The medicine is officially indicated for the reduction of elevated pressure inside the eye in patients diagnosed with open-angle glaucoma or ocular hypertension. Regulatory documents do not list other primary uses for the medicine.

---

Q: Is there a risk of a serious allergic reaction to Пролатан?

The use of the medicine is contraindicated in patients with a known hypersensitivity, meaning it should not be used if you have a known allergy to it. Officially reported serious reactions include symptoms such as swelling of the eyelid, eye redness, and blistering skin rash.

---

Q: Can Пролатан potentially affect the eye's sensitivity to light?

Sensitivity of the eye to light (photophobia) is a documented, though less common, side effect reported in official safety profiles for this medicine.

---

Q: What is the typical appearance of the medication (color or consistency)?

The medicine is described in official product information as a clear, colorless liquid or solution.

---

Q: What are the restrictions regarding driving or operating machinery after using Пролатан?

Instillation of the drops may cause a temporary blurring of vision. Official warnings indicate that activities such as driving or operating machinery should be avoided until any temporary blurring of vision has fully resolved.

---

Q: Is there information on potential interactions between Пролатан and common over-the-counter pain relievers or cold medicines?

While not directly related to cold medicines, regulatory documents note that studies have shown that the co-administration of certain topical Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) has been associated with conflicting reports of either increased or decreased eye pressure.

---

Q: What kind of monitoring (e.g., eye check-ups) is typically recommended while using Пролатан?

Official guidance suggests that follow-up appointments are necessary to measure eye pressure and monitor eyesight during the course of treatment.

---

Q: Does a history of severe asthma affect eligibility to use Пролатан?

The medicine should be used with caution in patients with a history of respiratory disorders like asthma. Regulatory agencies have received post-marketing reports of acute asthma or the worsening of pre-existing asthma symptoms.

---

Q: Does Пролатан use commonly cause or worsen symptoms of dry eye?

Yes, dry eye symptoms are a documented side effect, often listed in the common (ge 1/100 to <1/10) or other frequency categories in official safety profiles.

---

Q: What is the effect of Пролатан if taken alongside dietary supplements or herbal remedies?

Official prescribing information does not list any formal interactions between the eye drops and systemically taken herbal products or dietary supplements.

---

Q: Does Пролатан cure the underlying eye condition, or only help manage the pressure?

The medicine is formally indicated for the reduction of elevated pressure inside the eye. Regulatory documents frame its purpose as management, and do not make a claim that the medicine cures the underlying eye condition.

How to Store and Dispose of Latanoprost (Пролатан)

Official regulatory documents define specific storage and stability requirements for Latanoprost ophthalmic solution.

Storage Conditions

Container Status	Required Temperature Range	Shelf-Life Constraint
Unopened	Refrigerated (2 C to 8 C / 36 F to 46 F)	N/A
Opened (In-Use)	Room Temperature (Up to 25 C / 77 F)	Discard six weeks after opening

The solution must be protected from light during storage and must not be frozen. The product must be kept out of the sight and reach of children at all times.

Disposal

Any solution remaining after the six-week post-opening period must be discarded. Single-use containers must be discarded immediately after a dose is administered. Unused or expired medication should be disposed of according to local guidelines or drug take-back programs.